Boehringer Ingelheim: Venous Thromboembolism trials

The registry lists 17 Venous Thromboembolism studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 2 7Phase 3 4Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood ClotTerminatedNCT05966740Results posted
• RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous ThromboembolismCompletedNCT02596230Results posted
• Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of AgeCompletedNCT02223260Phase 2Results posted
• Safety of Dabigatran Etexilate in Blood Clot Prevention in ChildrenCompletedNCT02197416Phase 3Results posted
• Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)CompletedNCT01895777Phase 3Results posted
• BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement SurgeryCompletedNCT01225822Phase 2Results posted
• Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran EtexilateCompletedNCT01184989Phase 4Results posted
• Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement SurgeryTerminatedNCT01153698Results posted
• Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXACompletedNCT01139658Results posted
• Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of AgeCompletedNCT01083732Phase 2Results posted
• Safety and Tolerability of Dabigatran Etexilate in AdolescentsCompletedNCT00844415Phase 2Results posted
• Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip ArthroplastyCompletedNCT00657150Phase 3Results posted
• Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTECompletedNCT00558259Phase 3Results posted
• A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood ClotWithdrawnNCT05536791
• Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement SurgeryCompletedNCT02170935Phase 2
• BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement SurgeryCompletedNCT02170701Phase 2
• Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of AgeWithdrawnNCT01773174Phase 2